文献速递乳腺癌

阿贝西利联合内分泌治疗用于激素受体阳性、人表皮生长因子受体2阴性高危早期乳腺癌的辅助治疗:monarchE预先计划的總生存期中分析结果,包括5年疗效结局

Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes.
PubMed 文献 · J Clin Oncol · 2024-01-09

monarchE研究预设的OS期中分析显示,中位随访54个月时,阿贝西利联合内分泌治疗较单用内分泌治疗持续改善IDFS(HR 0.680,95%CI 0.599-0.772)和DRFS(HR 0.675,95%CI 0.588-0.774),5年IDFS和DRFS绝对获益分别加深至7.6%和6.7%;OS未达统计学显著(死亡208例 vs 234例),未观察到新的安全性信号。

要点

  • 中位随访54个月,阿贝西利联合内分泌治疗持续改善IDFS(HR 0.680)和DRFS(HR 0.675)。
  • 5年IDFS和DRFS绝对获益分别达7.6%和6.7%,较4年和3年持续加深。
  • OS未达统计学显著(阿贝西利组死亡208例 vs 单用内分泌治疗组234例),无新安全性信号。

核心结论

  • 阿贝西利联合内分泌治疗在完成治疗之后仍持续降低浸润性疾病和远处疾病复发风险。
  • 5年绝对获益增加与 carryover effect 一致,进一步支持在高危早期乳腺癌患者中使用阿贝西利。

研究设计与样本

  • monarchE研究预设的总体生存期中分析,报告5年疗效结果。
  • 意向治疗人群中,中位随访54个月。

主要发现

  • IDFS的HR为0.680(95%CI 0.599-0.772),DRFS的HR为0.675(95%CI 0.588-0.774)。
  • 5年IDFS和DRFS绝对改善分别为7.6%和6.7%,4年分别为6%和5.3%,3年分别为4.8%和4.1%。
  • 阿贝西利联合内分泌治疗组死亡208例,单用内分泌治疗组死亡234例,OS未达统计学显著。
  • 未观察到新的安全性信号。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Two years of adjuvant abemaciclib combined with endocrine therapy (ET) resulted in a significant improvement in invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) that persisted beyond the 2-year treatment period in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive, high-risk early breast cancer (EBC). Here, we report 5-year efficacy results from a prespecified overall survival (OS) interim analysis. In the intent-to-treat population, with a median follow-up of 54 months, the benefit of abemaciclib was sustained with hazard ratios of 0.680 (95% CI, 0.599 to 0.772) for IDFS and 0.675 (95% CI, 0.588 to 0.774) for DRFS. This persistence of abemaciclib benefit translated to continuous separation of the curves with a deepening in 5-year absolute improvement in IDFS and DRFS rates of 7.6% and 6.7%, respectively, compared with rates of 6% and 5.3% at 4 years and 4.8% and 4.1% at 3 years. With fewer deaths in the abemaciclib plus ET arm compared with the ET-alone arm (208 v 234), statistical significance was not reached for OS. No new safety signals were observed. In conclusion, abemaciclib plus ET continued to reduce the risk of developing invasive and distant disease recurrence beyond the completion of treatment. The increasing absolute improvement at 5 years is consistent with a carryover effect and further supports the use of abemaciclib in patients with high-risk EBC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Rastogi P, O'Shaughnessy J, Martin M, et al. Adjuvant Abemaciclib Plus Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, High-Risk Early Breast Cancer: Results From a Preplanned monarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes. J Clin Oncol. 2024. PMID: 38194616. doi:10.1200/JCO.23.01994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。